Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGSWW) Other Operating Expenses (2021 - 2024)

GeneDx Holdings has reported Other Operating Expenses over the past 4 years, most recently at $2.6 million for Q4 2024.

  • Quarterly results put Other Operating Expenses at $2.6 million for Q4 2024, down 20.59% from a year ago — trailing twelve months through Sep 2025 was $2.6 million (up 285.59% YoY), and the annual figure for FY2023 was -$2.0 million, up 69.0%.
  • Other Operating Expenses for Q4 2024 was $2.6 million at GeneDx Holdings, up from -$774000.0 in the prior quarter.
  • Over the last five years, Other Operating Expenses for WGSWW hit a ceiling of $13.0 million in Q2 2021 and a floor of -$2.8 million in Q3 2023.
  • Median Other Operating Expenses over the past 4 years was -$874000.0 (2024), compared with a mean of $705080.0.
  • Peak annual rise in Other Operating Expenses hit 306.38% in 2023, while the deepest fall reached 64.64% in 2023.
  • GeneDx Holdings' Other Operating Expenses stood at $13.0 million in 2021, then plummeted by 112.3% to -$1.6 million in 2022, then soared by 306.38% to $3.3 million in 2023, then dropped by 20.59% to $2.6 million in 2024.
  • The last three reported values for Other Operating Expenses were $2.6 million (Q4 2024), -$774000.0 (Q3 2024), and -$874000.0 (Q2 2024) per Business Quant data.